Mostrar el registro sencillo del ítem

Effect of Peg-IFN on the viral kinetics of HDV infected patients treated with bulevirtide

dc.rights.licenseopenen_US
dc.contributor.authorEL MESSAOUDI, Selma
dc.contributor.authorBRICHLER, Segolene
dc.contributor.authorFOUGEROU-LEURENT, Claire
dc.contributor.authorGORDIEN, Emmanuel
dc.contributor.authorGERBER, Athenaïs
dc.contributor.authorKORTEBI, Amal
dc.contributor.authorLAGADIC, Garance
dc.contributor.authorSUBIC-LEVRERO, Miroslava
dc.contributor.authorMÉTIVIER, Sophie
dc.contributor.authorPOL, Stanislas
dc.contributor.authorMINELLO, Anne
dc.contributor.authorRATZIU, Vlad
dc.contributor.authorLEROY, Vincent
dc.contributor.authorMATHURIN, Philippe
dc.contributor.authorALRIC, Laurent
dc.contributor.authorCOULIBALY, Fatoumata
dc.contributor.authorPAWLOTSKY, Jean-Michel
dc.contributor.authorZOULIM, Fabien
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorDE LEDINGHEN, Victor
dc.contributor.authorGUEDJ, Jérémie
dc.contributor.authorGROUP, Anrs Hd Ep Buledelta Study
dc.date.accessioned2024-10-11T06:53:42Z
dc.date.available2024-10-11T06:53:42Z
dc.date.issued2024-08-01
dc.identifier.issn2589-5559en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202411
dc.description.abstractEnBackground & AimsBulevirtide is a first-in-class entry inhibitor antiviral treatment for chronic hepatitis D. The viral kinetics during bulevirtide therapy and the effect of combining bulevirtide with Peg-IFN are unknown.MethodsWe used mathematical modeling to analyze the viral kinetics in two French observational cohorts of 183 patients receiving bulevirtide with or without Peg-IFN for 48 weeks.ResultsThe efficacy of bulevirtide in blocking cell infection was estimated to 90.3%, while Peg-IFN blocked viral production with an efficacy of 92.4%, albeit with large inter-individual variabilities. The addition of Peg-IFN to bulevirtide was associated with a more rapid virological decline, with a rate of virological response (>2 log of decline or undetectability) at week 48 of 86.9% (95% PI = [79.7;95.0]), compared to 56.1% (95% PI = [46.4;66.7]) with bulevirtide only. The model was also used to predict the probability to achieve a cure of viral infection, with a rate of 8.8% (95% PI = [3.5;13.2]) with bulevirtide compared to 18.8% (95% PI = [11.6;29.0]) with bulevirtide+Peg-IFN. Mathematical modeling suggests that after 144 weks of treatment, the rates of viral cure could be 42.1% (95% PI= [33.3;52.6]) with bulevirtide and 66.7% (95% PI= [56.5;76.8]) with bulevirtide+Peg-IFN.ConclusionsIn this analysis of real-world data, Peg-IFN strongly enhanced the kinetics of viral decline in patients treated with bulevirtide. Randomized clinical trials are warranted to assess the virological and clinical benefit of this combination, and to identify predictors of poor response to treatment.Impact and ImplicationBulevirtide has been approved for Chronic HDV infection by regulatory agencies in Europe based on its good safety profile and rapid virological response after treatment initiation, but the optimal duration of treatment and the chance to achieve a sustained virological response remain unknown. The results presented in this study have a high impact for clinicians and investigators as they provide important knowledge on the long-term virological benefits of a combination of peg-IFN and bulevirtide in CHD patients. Clinical trials are now warranted to confirm those predictions.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enAntiviral treatment
dc.subject.enBulevirtide
dc.subject.enHepatitis delta virus
dc.subject.enPeg-IFN
dc.subject.enViral kinetics
dc.title.enEffect of Peg-IFN on the viral kinetics of HDV infected patients treated with bulevirtide
dc.title.alternativeJHEP Repen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jhepr.2024.101070en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39100818en_US
bordeaux.journalJHEP Reports Innovation in Hepatologyen_US
bordeaux.page101070en_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-04526834
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=JHEP%20Reports%20%20Innovation%20in%20Hepatology&rft.date=2024-08-01&rft.volume=6&rft.issue=8&rft.spage=101070&rft.epage=101070&rft.eissn=2589-5559&rft.issn=2589-5559&rft.au=EL%20MESSAOUDI,%20Selma&BRICHLER,%20Segolene&FOUGEROU-LEURENT,%20Claire&GORDIEN,%20Emmanuel&GERBER,%20Athena%C3%AFs&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_JHEP_2024_Messaoudi.pdf
Tamaño:
4.001Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem